Workflow
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®
ATHEAlterity Therapeutics(ATHE) GlobeNewswire News Room·2024-10-02 11:35
  • ATH434 shows promise as a disease-modifying therapy for MSA - - ATH434-202 Phase 2 interim data demonstrate stabilization of clinical symptoms and biomarkers in clinical responders - MELBOURNE, Australia and SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presentations were p ...